Selective iron chelation in Friedreich ataxia: biologic and clinical implications
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Genetic disorders of iron metabolism and chronic inflammation often evoke local iron accumulation. In Friedreich ataxia, decreased iron-sulphur cluster and heme formation leads to mitochondrial iron accumulation and ensuing oxidative damage that primarily affects sensory neurons, the myocardium, and endocrine glands. We assessed the possibility of reducing brain iron accumulation in Friedreich ataxia patients with a membrane-permeant chelator capable of shuttling chelated iron from cells to transferrin, using regimens suitable for patients with no systemic iron overload. Brain magnetic resonance imaging (MRI) of Friedreich ataxia patients compared with age-matched controls revealed smaller and irregularly shaped dentate nuclei with significantly (P < .027) higher H-relaxation rates R2*, indicating regional iron accumulation. A 6-month treatment with 20 to 30 mg/kg/d deferiprone of 9 adolescent patients with no overt cardiomyopathy reduced R2* from 18.3 s−1 (± 1.6 s−1) to 15.7 s−1 (± 0.7 s−1; P < .002), specifically in dentate nuclei and proportionally to the initial R2* (r = 0.90). Chelator treatment caused no apparent hematologic or neurologic side effects while reducing neuropathy and ataxic gait in the youngest patients. To our knowledge, this is the first clinical demonstration of chelation removing labile iron accumulated in a specific brain area implicated in a neurodegenerative disease. The use of moderate chelation for relocating iron from areas of deposition to areas of deprivation has clinical implications for various neurodegenerative and hematologic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“clinical symptoms include cardiac hypertrophy [1128] and (pre-)diabetes [1129], consistent with the general thesis described here that all are in part manifestations of iron dysregulation, and in which suitable chelation may be beneficial [1130,1131]”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1130]
In the citing paper
“appropriate iron chelation may have therapeutic benefits”
In the citing paper
“A reduction in iron content was seen after 2 months of treatment and the effect was proportional to the concentration of initial accumulated iron.”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [210]
In the citing paper
“None of the other brain regions investigated (ie, pallidal nuclei, the thalamus, and cerebellar white matter region) showed any substantial changes in iron accumulation as detected by T2*-weighted MRI throughout chelation therapy.”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [210]
In the citing paper
“Treatment with 20 mg/kg per day or 30 mg/kg per day deferiprone for 6 months in nine patients with Friedreich’s ataxia aged between 14 and 23 years reduced the iron content in the dentate nuclei. This reduction was associated with neurological improvements in manipulative dexterity, speech fluency, and a reduction in neuropathy and ataxia gait, particularly in the youngest patients.”
From The role of iron in brain ageing and neurodegenerative disorders (2014) · cites this paper as [210]
Citations
Cites
Free radicals in biology and medicine
(1991) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(91)90478-o · Cited by 17,178
Free Radicals in Biology and Medicine
Land, E. T. (1990) · International Journal of Radiation Biology · doi:10.1080/09553009014552071 · Cited by 4,854
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion
Campuzano, V., Montermini, L., Moltò, M. D., Pianese, L., Cossée, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A., et al. (1996) · Science · doi:10.1126/science.271.5254.1423 · Cited by 2,786 · cited 1×
“In Friedreich ataxia (FA), an expansion of a GAA repeat in the first intron of the nuclear encoded frataxin gene (5,6), results in underexpression of a”
BackgroundImaging iron stores in the brain using magnetic resonance imaging
Haacke, E. M., Cheng, N. Y. C., House, M. J., Liu, Q., Neelavalli, J., Ogg, R. J., Khan, A., Ayaz, M., Kirsch, W., & Obenaus, A. (2005) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2004.10.001 · Cited by 995
Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia
Rötig, A., de Lonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., Munnich, A., & Rustin, P. (1997) · Nature Genetics · doi:10.1038/ng1097-215 · Cited by 991
Self-citationWang, G., & Semenza, G. (1993) · Blood · doi:10.1182/blood.v82.12.3610.3610 · Cited by 766
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Non-invasive assessment of hepatic iron stores by MRI
Gandon, Y., Olivié, D., Guyader, D., Aubé, C., Oberti, F., Sebille, V, & Deugnier, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15436-6 · Cited by 671
Pennell, D. J. (2006) · Blood · doi:10.1182/blood-2005-07-2948 · Cited by 495
Cited by
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
Knovich, M. A., Storey, J. A., Coffman, L. G., Torti, S. V., & Torti, F. M. (2009) · Blood Reviews · doi:10.1016/j.blre.2008.08.001 · Cited by 627
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5593 · Cited by 619
Self-citationIron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 578
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Metadata
- Authors
- Boddaert, N., Le Quan Sang, K. H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.-C., Munnich, A., & Cabantchik, Z. I.
- Affiliations
- Pediatric Radiology Unit and
- Medical Genetic Clinic and Research Unit, Institut National de la Santé et de la Recherche Médicale (INSERM) 781, Hôpital Necker-Enfants Malades and Université Paris V René Descartes, Paris, France;
- Hôpital Necker-Enfants Malades (FR)
- U2R2M, Centre national de la recherche scientifique (CNRS) UMR 8081, Université Paris Sud, Orsay, France;
- Pediatric Unit, Hôpital de Montluçon, Montluçon, France;
- Hebrew University of Jerusalem (IL)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-07-01
- Volume
- 110
- Issue
- 1
- Pages
- 401-408
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2022708198
- Cited by
- 409
- References
- 63
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 12 · 2023: 14 · 2022: 16 · 2021: 20 · 2020: 18 · 2019: 22 · 2018: 22 · 2017: 15 · 2016: 20 · 2015: 12 · 2014: 28 · 2013: 28 · 2012: 38
- FWCI
- 19.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- Friedreich's ataxia, iron chelation, deferiprone, brain iron accumulation, dentate nucleus, R2* relaxation rate, iron-sulfur clusters, mitochondrial iron, neurodegeneration, iron metabolism disorders, neuropathy, ataxia
- MeSH terms
- Deferiprone, Adolescent, Adult, Biological Transport, Brain, Brain Chemistry, Female, Friedreich Ataxia, Humans, Iron, Iron Chelating Agents, Magnetic Resonance Imaging, Male, Pyridones, Case-Control Studies, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective iron chelation in Friedreich ataxia: biologic and clinical implications. https://app.cochat.ai/papers/10.1182/blood-2006-12-065433
- The paper
- Boddaert, N., Le Quan Sang, K. H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.-C., Munnich, A., & Cabantchik, Z. I. (2007). Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. https://doi.org/10.1182/blood-2006-12-065433
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.